Quick answers
- What is Ziprasidone used for?
- The FDA-approved label (Ziprasidone Hydrochloride, Bryant Ranch Prepack, August 11, 2026) says: “Ziprasidone capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Ziprasidone have a boxed warning?
- Yes. The FDA label for Ziprasidone Hydrochloride has a boxed warning (“WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Ziprasidone?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Ziprasidone been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started May 31, 2023 (Class I). A recall usually concerns specific lots, not every product.
- Who makes Ziprasidone?
- 25 companies list prescription products of Ziprasidone in the FDA NDC Directory, including Bryant Ranch Prepack, Remedyrepack Inc. and Viatris Specialty LLC.
What Ziprasidone is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Ziprasidone capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. …
— FDA label: Ziprasidone Hydrochloride, Bryant Ranch Prepack, effective August 11, 2026. Read the full label on DailyMed →
The FDA has 38 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
. Read it on the full label →
38 of 38 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Capsule · Injection, powder, lyophilized, for solution |
|---|---|
| Route | Oral · Intramuscular |
| Prescription products | 83 in the FDA NDC Directory |
| Brand names | Geodon |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| ziprasidone 80 mg capsule | Brand: Geodon | $31.11 per capsule |
| ziprasidone hydrochloride 20 mg capsule | Generic | $0.2181 per capsule |
| ziprasidone hydrochloride 40 mg capsule | Generic | $0.2648 per capsule |
| ziprasidone hydrochloride 60 mg capsule | Generic | $0.3324 per capsule |
| ziprasidone hydrochloride 80 mg capsule | Generic | $0.2717 per capsule |
| ziprasidone mesylate 20 mg/mL injection, powder, lyophilized, for solution | Generic | $21.81 per unit |
NADAC list of November 4, 2026; these prices took effect between June 3, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack8 products
- Remedyrepack Inc.8 products
- Viatris Specialty LLC5 products
- NorthStar Rx LLC4 products
- Apotex Corp.4 products
- Macleods Pharmaceuticals Limited4 products
- AvPAK4 products
- Golden State Medical Supply, Inc.4 products
- Chartwell RX, LLC4 products
- Aurobindo Pharma Limited4 products
- BluePoint Laboratories4 products
- Dr. Reddy's Laboratories Limited4 products
- American Health Packaging4 products
- Major Pharmaceuticals4 products
- Roerig4 products
- Proficient Rx LP3 products
- NuCare Pharmaceuticals, Inc.2 products
- Fosun Pharma USA Inc.2 products
- Dr. Reddy's Laboratories Inc.2 products
- A-S Medication Solutions1 product
- Steriscience Specialties Private Limited1 product
- Armas Pharmaceuticals Inc.1 product
- HF Acquisition Co LLC, DBA HealthFirst1 product
- Gland Pharma Limited1 product
- Novadoz Pharmaceuticals LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA020825 GEODON | Viatris | February 5, 2001 | 34, latest January 22, 2025 2025: Labeling · 2022: Efficacy · 2021: Labeling |
| NDA020919 GEODON | Viatris | June 21, 2002 | 26, latest January 22, 2025 2025: Labeling · 2021: Labeling · 2020: Labeling |
Generic approvals (8)
- ANDA077561Apotex · March 2, 2012
- ANDA077565DR Reddys Labs Inc · March 2, 2012
- ANDA090348Chartwell Rx · September 5, 2012
- ANDA204117Aurobindo Pharma · December 27, 2016
- ANDA204375Macleods Pharms · February 17, 2017
- ANDA211908Gland · December 26, 2019
- ANDA216091Msn · September 15, 2022
- ANDA217595Steriscience · September 3, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
May 31, 2023 · Class I · Terminated · D-0893-2023
Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg.
ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg, Unit Dose Carton 40 Capsules, Rx only, Mfd. By: Dr. Reddy's Laboratories Limited Bachupally-500 090 India, Distributed by: Major Pharmaceuticals Livonia, MI 48152 USA, NDC 0904-6 — The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Ziprasidone Hydrochloride, Bryant Ranch Prepack, effective August 11, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →